VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 901–1,000 of 1,000
Jiang, X. M., Aljbri, A., Liu, J., Shang, L., Tian, Y., & Shao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1401882 · Cited by 3
“It can potentially increase the effectiveness of anti-PD-1 and antiprogrammed death ligand 1 (PD-L1) treatments by counteracting VEGF-mediated immunosuppression and encouraging T-cell in fi ltration into tumors (13).”
BackgroundLi, H., Ruan, Z., Jia, Y., Zhang, Y., Wang, L., Yang, Y., Wang, R., & Fang, J. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16242 · Cited by 3
“15 18 Studies have demonstrated that targeting VEGF/VEGFR therapy can not only inhibit neovascular formation but also normalize the tumour micro-environment through increased infiltration of T cells, 19 and the normalization of the tumour microenvironment can enhance the efficacy of immunotherapy…”
Saeed, A., Colby, S., Oberstein, P. E., Duda, D. G., Park, R., Agarwal, R., Figueroa-Moseley, C., Vaidya, R., Unger, J. M., Guthrie, K. A., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2485020 · Cited by 3
Han, X., Qin, S., Liu, S., & Li, Z. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03887-y · Cited by 7
“…regulate the immune microenvironment, such as the Treg cell proliferation, programmed cell death 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), T-cell immunoglobulin mucin family member 3 (Tim-3), and lymphocyte-activation gene 3 (Lag-3)] on intratumoral CD8 + T cells [41, 42].”
Huang, Y., Shen, S., Liu, C., Pavlidis, S. P., Wang, C., Ko, H., Chung, F., Lin, T., Feng, P., Lee, K., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12875 · Cited by 3
Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios
Çetin, B., & Koşar, A. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02264-5 · Cited by 3
The Human Tumor Microenvironment
Vano, Y. A., Giraldo, N. A., Fridman, W. H., & Sautès‐Fridman, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_2 · Cited by 5
When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma
Wainsztein, V., & Chen, T. W. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-19-37 · Cited by 3
Mechanisms of resistance to immune checkpoint inhibitors
Liu, X., & Guan, Q. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i17.857 · Cited by 3
Nakahama, K., Kaneda, H., Osawa, M., Fukui, M., Izumi, M., Yoshimoto, N., Sugimoto, A. K., Nagamine, H., Ogawa, K., Matsumoto, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15464 · Cited by 3
Immunotherapy of advanced hepatocellular carcinoma: case report and literature review
Меньшиков, К. В., Султанбаев, А. В., Мусин, Ш. И., Menshikovа, I. A., Abdeev, R. R., Султанбаева, Н. И., Nigmatullin, V. G., & Popova, E. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-9-31-39 · Cited by 3
Microfluidics for Immuno‐oncology
Ma, C., Harris, J., Morales, R. T., & Chen, W. (2019) · Wiley eBooks · doi:10.1002/9783527818341.ch5 · Cited by 5
Dammeijer, F. F., Dumoulin, D. W., & Aerts, J. G. J. V. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.001 · Cited by 3
Angiogenesis inhibition in lung cancer: emerging novel strategies.
Lazzari, C., Bulotta, A., Damiano, G., Mirabile, A., Viganó, M., Veronesi, G., & Gregorc, V. (2022) · PubMed · doi:10.1097/cco.0000000000000807 · Cited by 3
“Furthermore, VEGF inhibits the differentiation of CD8þ and CD4þ T cells [36,37], and decreases T cells and natural killer cells (NK) cytotoxicity.”
BackgroundOshima, M., Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Nakayama, A., Nagamoto, S., Nakayama, T., Izumi, K., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100106 · Cited by 2
Yamaguchi, Y., Shinno, Y., Masuda, K., Ariyasu, R., Nosaki, K., Hakozaki, T., Tokito, T., Nomura, S., Nishio, M., Goto, K., et al. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101200 · Cited by 2
Mita, Y., Teishima, J., Hara, T., Ueki, H., Wakita, N., Okamura, Y., Suzuki, K., Bando, Y., Terakawa, T., Chiba, K., et al. (2025) · International Journal of Urology · doi:10.1111/iju.70065 · Cited by 2
Wang, J., Yu, S., Liang, Q., Wu, Y., Zhang, W., & Awadasseid, A. (2025) · ChemMedChem · doi:10.1002/cmdc.202500738 · Cited by 2
Lv, X., Tan, X., Xiao, Z., Chen, W., & Xu, Y. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2585347 · Cited by 2
“In TME, tumor cells produce VEGF-A, which can upregulate the PD-1, Cytotoxic T-lymphocyte antigen 4 (CTLA-4), and T-cell Immunoglobulin and Mucin-domain containing protein 3 (TIM-3) on the surface of CD8 + T cells, thus inducing T cell exhaustion [39].”
Targeting urological cancers with CAR-T cell therapy: current landscape and future directions
Chen, K., Wang, Y., Zhang, P., He, Y., Wusiman, D., Yoo, K. H., Lin, L., Hu, Q., Wu, W., Wu, L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07737-7 · Cited by 3
“For example, RCC features pronounced hypoxia and pathological angiogenesis, substantially impeding immune cell activity [280, 281].”
Reprogramming the tumor immune microenvironment via antibody-drug conjugates
Xu, T., Gu, Y., & Guan, X. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642215 · Cited by 2
“VEGF-A not only orchestrates tumor angiogenesis, but emerging evidence also demonstrates that it upregulates the expression of PD-1 on the surface of CTLs via the VEGFR2/PLCγ/NFAT signaling pathway, thereby inducing CTL exhaustion [53,54].”
Perez-Gracia, J. L., Mellado, B., Hansen, A. R., Alonso‐Gordoa, T., Gomez‐Roca, C., Eefsen, R. L., Négrier, S., Suárez, C., Lee, J., Hussain, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012466 · Cited by 3
Optimization of Chelator Conjugation to PD-1/VEGF Bispecific Antibody for 89 Zr-ImmunoPET Imaging
Jiang, Y., Hou, X., Hao, S., Chen, Q., Zhang, Q., Zhang, Y., Yang, Z., & Zhu, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00574 · Cited by 2
The Role and Mechanisms of Tumor-Derived Exosomes in the Formation of the Premetastatic Niche
王继超, & Ye, J. (2026) · Cancer Control · doi:10.1177/10732748261448980 · Cited by 3
Gafanov, R. A., Dzidzaria, A. G., Борисович, К. И., & Фастовец, С. В. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-3-29-37 · Cited by 2
“Таким образом, изменения в гене VHL облегчают онкогенный процесс благодаря иммуносупрессивному эффекту, потенциально влияя одновременно на праймирование, перенос и проникновение Т-клеток [34, 43].”
How, J., Jazaeri, A. A., Fu, S., Rodon, J. A., Gong, J., Stephen, B., Pria, H. R. F. D., Bhosale, P., Johnson, A. M., Yuan, Y., et al. (2022) · Cancers · doi:10.3390/cancers14153695 · Cited by 3
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
The interaction between end-metabolites and immune escape
Zhu, T., & Wang, G. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0573-3 · Cited by 4
Chatterjee, S. S., & Sanjeev, B. S. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106386 · Cited by 2
Nagai, H., Mukozu, T., Matsui, T., Mohri, K., Nagumo, H., Yoshimine, N., Kobayashi, K., Ogino, Y., Daido, Y., Wakui, N., et al. (2024) · Oncology · doi:10.1159/000537965 · Cited by 2
“…cell maturation and T-cell priming [5 – 7]; (2) normalizing tumor vasculature and increasing cytotoxic T-cell in fi ltration into the tumor [6, 8 – 11]; and (3) counteracting immunosuppression in the tumor microenvironment by reducing bone marrow-derived suppressor cells and Treg cells [6, 11 – 15].”
He, W., Tong, L., Yang, W. J., Yuan, Y., Li, Y., & Tang, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1298389 · Cited by 3
Hou, Z., Lai, L., Wu, H., Zou, B., Xu, N., Zhu, D., Wang, X., & Zhang, H. (2024) · Journal of Cancer · doi:10.7150/jca.96514 · Cited by 3
“It results in decreased expression of PD-1 and CTLA-4 on immune cells [26].”
BackgroundDu, Y., An, C., & Liu, W. (2024) · International Journal of Hyperthermia · doi:10.1080/02656736.2024.2380001 · Cited by 2
“Indeed, combined antiangiogenic and anti-PD-1/PD-L1 therapy has been shown to elicit T-cell function and drive tumor cells to activate immune checkpoints [29–31], thereby generating greater antitumour immunity than HAIC or TACE alone.”
Scheck, M. K., Goetze, T. O., Ettrich, T. J., Schmalenberg, H., Clemens, M., Mahlberg, R., Heeg, S., Kanzler, S., Hapke, G., Thuss-Patience, P., et al. (2024) · Oncology Research and Treatment · doi:10.1159/000541174 · Cited by 2
“In this context, it is also noteworthy that the immunomodulatory effects of anti-VEGFR inhibitors on tumor microenvironment are discussed to potentially overcome resistance to prior immune checkpoint therapy [31 – 33].”
Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
Komori, T., Koizumi, S., Inoue, S., Yamaura, M., Murayama, Y., Otsuka, A., & Nakamura, Y. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100277 · Cited by 3
Moussa, M. J., Kovalenko, I., Crupi, E., Proskuriakova, E., Geng, Y., Fallara, G., Benkhadra, R., Raggi, D., Campbell, M. T., Msaouel, P., et al. (2024) · Bladder Cancer · doi:10.1177/23523735241296763 · Cited by 2
Takano, E. A., Jana, M. K., Gonzalez, L. E. L., Pang, J.-M. B., Salgado, R., Loi, S., & Fox, S. B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317331 · Cited by 2
Ishihara, M., Kawamura, T., Namba, Y., Takeyasu, Y., Hasegawa, Y., Sato, Y., Negi, Y., Oba, T., Sumi, T., Hirata, H., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251344010 · Cited by 3
Chu, A., & Wang, Y. (2025) · Genes · doi:10.3390/genes16101140 · Cited by 2
“Targeting immune checkpoints and immune-infiltrating cells within the TIME can enhance anti-tumor immune responses and improve the efficacy of ICIs, with combination therapies such as PD-1/CTLA-4 dual blockade emerging as a principal strategy to enhance the therapeutic outcomes of ICI [83–85].”
Role of cytokine-based immunotherapy approaches in gastrointestinal cancers
ElBeblawy, R., Malla, M., & Akce, M. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.10.005 · Cited by 2
Hagiwara, S., Nishida, N., & Kudo, M. (2021) · Liver Cancer · doi:10.1159/000516692 · Cited by 2
Immunité antitumorale (mécanismes, immunoediting, immunosurveillance)
Guillebon, É. D., & Tartour, É. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2542-z · Cited by 2
Colle, E., André, T., Lebbé, C., & Borg, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2664-y · Cited by 2
“D’après un modèle murin, la présence de VEGF favorise aussi l’expression de PD-1 sur les lymphocytes T lors de leur activation [68].”
BackgroundSome aspects of immunotherapy in colon cancer
Fedyanin, M. Y., Эльснукаева, Х. Х.-М., Tryakin, A. A., & Tyulyandin, S. А. (2018) · Surgery and Oncology · doi:10.17650/2220-3478-2018-8-1-19-27 · Cited by 3
Wang, J., Peng, W., Jiang, M., & Wu, L. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.05 · Cited by 2
Signaling in the tumor microenvironment of therapy-resistant glioblastoma
Nikolopoulos, M., & Das, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00004-x · Cited by 2
Overexpression of VEGF in the MOPC 315 Plasmacytoma Induces Tumor Immunity in Mice
Kim, B., Choi, S. H., Letterio, J. J., Song, J. Y., & Huang, A. Y.-C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095235 · Cited by 2
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma
Carloni, R., Rizzo, A., Cusmai, A., Palloni, A., Federico, A. D., Marco, M. D., Massafra, R., Fanizzi, A., Palmiotti, G., & Brandi, G. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0045 · Cited by 2
Komatsu, S., Yano, Y., Kido, M., Kuramitsu, K., Gon, H., Fukushima, K., Urade, T., So, S., Yamamoto, A., Goto, T., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.16053 · Cited by 3
Bottlenecks and opportunities in immunotherapy for glioma: a narrative review
Shi, Y. K., Wu, M., Liu, Y., Chen, L., Bian, X., & Xu, C. S. (2022) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000135 · Cited by 3
“[95] VEGF-induced inhibitory checkpoints (eg, PD1 and T-cell immunoglobulin and mucin domain 3) on DCs or CD8+ T cells are found to revert once the VEGF-VEGFR interaction is blocked.[96] Under antiangiogenic therapy, normalized tumor blood vessels demonstrate restored ability of drug penetration; drug uptake by tumor…”
BackgroundDevelopment of Tumor Markers for Breast Cancer Immunotherapy
Fang, Q., Shen, G., Xie, Q., Guan, Y., Liu, X., Ren, D., Zhao, F., Liu, Z., Ma, F., & Zhao, J. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230508152817 · Cited by 2
Ramucirumab plus pembrolizumab: can we make the maths work?
Klempner, S. J., & Wainberg, Z. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30399-7 · Cited by 2
Barbosa, A. E. D. S., Azevedo-Martins, J. M., Lopes, B. A., Giardini, I. J. M., & Halder, C. V. F. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n4-250 · Cited by 2
Antiangiogenic drugs as chemosensitizer in melanoma
Quaresmini, D., & Guida, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00003-2 · Cited by 1
Saito, M., Suzuki, K., Tamaki, S., Kimura, Y., Abe, I., Endo, Y., Watanabe, F., & Rikiyama, T. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2715 · Cited by 1
“The enhanced effect of an ICI in combination with angiogenesis inhibitors has already been reported in lung, renal, and hepatocellular carcinomas (18,19).”
BackgroundAmadeo, E., Foti, S., Camera, S., Rossari, F., Persano, M., Prinzi, F. L., Vitiello, F., Gardini, A. C., & Rimini, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377321 · Cited by 1
Wang, T., Wang, J., Zhang, Y., Song, Y., Xu, G., & Zhang, B. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001660 · Cited by 1
“As antiangiogenic agents may reverse PD-1-induced CD8(+) T cell exhaustion [5], the combination of VEGF-targeted agents with immune checkpoint inhibitors offers superior efficacy compared to monotherapy in many solid tumors [6].”
Joshkon, A., Traboulsi, W., Terme, M., Bachelier, R., Fayyad‐Kazan, H., Dignat‐George, F., Foucault‐Bertaud, A., Leroyer, A. S., Bardin, N., & Blot‐Chabaud, M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0008 · Cited by 4
Self-citationInada, S., Omori, K., Nomura, T., Kitagawa, H., Shigemoto, N., Hattori, N., & Ohge, H. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.102596 · Cited by 1
Ji, Y., Guo, J., Jiang, H., Ren, W., Geng, J., Lei, M., Li, J., Dang, P., Wang, Y., Chen, X., et al. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096344636250101074632 · Cited by 1
Cui, S., Fan, L., Sun, X., Cai, Y., Wang, T., Li, P., Wang, R., & Liu, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.14990 · Cited by 1
Lu, Y., Lin, J., Lu, Y., Lin, L., Zheng, S., Chen, Y., & Huang, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323023 · Cited by 2
“In tumor patients, the production of VEGF-A in the tumor microenvironment enhances the expression of PD-1 and other inhibitory checkpoints associated with CD8 + T-cell exhaustion, which is reversed by anti-VEGF/VEGFR therapy and enhances the antitumour effects of anti-PD-1/PD-L1 antibodies [54].”
Wang, H., Zheng, J., Pan, J., Li, S., Ren, B., Wang, P., & Mo, B. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-04945-3 · Cited by 1
“Preclinical studies suggest synergistic effects between ICIs and anti-angiogenic drugs, as VEGF inhibition may reverse immunosuppressive microenvironments [8].”
Zhang, C., Bi, J., Huang, Y., Ke, Z., Yuan, Z., Ruan, H., Pi, G., Li, Y., Shao, J., & Han, G. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102952 · Cited by 1
Sun, M., Yang, P., Yang, T., Zhang, J., Li, H., Li, Y., & Zhu, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1611284 · Cited by 4
Loizidis, S., Vogazianos, P., Kordatou, Z., Fotopoulos, G., Orphanos, G. S., Kyriakou, F., & Charalambous, H. (2025) · Current Oncology · doi:10.3390/curroncol32110612 · Cited by 3
“It was also noted that in lung cancer, VEGF-A inhibits CD8+ T-cell activation, leading them to exhaustion [34].”
Mori, H., Maehira, H., Nitta, N., Fujimoto, S., Maekawa, T., Miyake, T., Kaida, S., Takebayashi, K., Sonoda, T., & Tani, M. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02265-1 · Cited by 1
“VEGF has profound immunosuppressive effects: it impairs dendritic cell maturation, reduces antigen presentation, enhances the proliferation of regulatory T cells and myeloid-derived suppressor cells, and limits trafficking of effector T cells [ 18, 19].”
Yan, J., Dong, H., Wu, C., Gu, H., Qi, Z., Chen, T., Hu, B., Zhou, H., & Long, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1667445 · Cited by 1
“VEGF promotes the development of defective tumor blood vessels that exhibit both structural and functional irregularities, leading to an abnormal TME under aberrant conditions of interstitial hypertension, hypoxia, and acidosis.”
InfluentialHu, L., Qi, F., Liu, H., Cao, Y., Li, Q., Liang, H., Liu, X., Du, Z., Wang, Y., & Wang, J. (2026) · Biomedicines · doi:10.3390/biomedicines14020363 · Cited by 1
“Furthermore, the enrichment of VEG-FA-related signaling in these cases suggests that anti-angiogenic agents could be leveraged to potentially convert this immunosuppressive “cold” microenvironment [36,37], offering a more tailored precision strategy for children with aggressive disease.”
Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer
Huang, X., Chen, C., Zeng, H., Wang, L., Chen, M., Liu, J., Wu, F., & Huang, W. (2026) · Oncology Research and Treatment · doi:10.1159/000551064 · Cited by 1
“This process has been shown to suppress the immune response [56–63].”
Onco-hypertension: hypertension induced by VEGF pathway inhibition
Palaskas, N. L., Kim, J. H., Moreno, S. F. L., Casso-Chapa, B., Beinart, N. I., Nnanna, N., Mendoza, K. C. O., Deswal, A. M., Yusuf, S. W., Koutroumpakis, E., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1748445 · Cited by 1
“…expanding regulatory T cells, and increasing myeloid-derived suppressor cells (MDSCs), VEGF promotes tumor immune evasion—mechanisms corroborated in translational studies and consistent with the synergy observed when VEGF blockade is combined with immune checkpoint inhibitors (16, 17) (Figure 1).”
Quintás‐Cardama, A., Sanmartín, E., Garcia-Gimenez, A., Muñoz-Langa, J., Collado, A., Suárez, C., del Muro, X. G., Méndez-Vidal, M. J., García-Sánchez, J., Coloma, C. S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1639330 · Cited by 1
Cancer Cell-Intrinsic Programs That Shape Tumor Immune Ecosystems
Wang, L., Guo, Y., Ma, L., & Miao, K. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.33 · Cited by 1
Wang, Y., MaoYan, T., Peng, C., Yang, J., Liu, F., Ding, D., Guo, Y., Yu, Y., & Han, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116821 · Cited by 2
Feng, Y., Wang, Y., Li, X., Wang, Y., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810065 · Cited by 3
“Moreover, VEGF dampens DC maturation and T-cell activation while simultaneously recruiting MDSCs and Tregs to the TME, further promoting an immunosuppressive environment (126).”
Geindreau, M., Pignol, C., Coënon, L., Varin, A., Racoeur, C., Milian, L. M., Roger, N., Chalmin, F., Vernet, T., Alibert, L., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015243 · Cited by 1
“28 VEGF has been shown to suppress T cell proliferation.”
Yanchu, L., Hongbin, W., Xiaoli, Y., Li, Z., Jun, W., Meiling, R., Xiaoyan, Y., Lei, L., & Feng, W. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04434-8 · Cited by 1
“…populations, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), induces FasL expression on tumor endothelium that selectively eliminates CD8 ⁺ T cells, and upregulates inhibitory checkpoints, including PD-1, CTLA-4, TIM-3, and LAG-3, on T cells [37, 38].”
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
“Furthermore, this pathway contributes to tumor immune evasion by modulating the tumor immune microenvironment—for example, by inhibiting T-cell infiltration (Voron et al., 2015).”
Immunothérapie en uropathologie
Verkarre, V., Roussel, H., Granier, C., Tartour, É., & Allory, Y. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.015 · Cited by 1
Drivers of EMT and Immune Evasion
Brekken, R. A., & Wnuk-Lipińska, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_9 · Cited by 1
Nano-therapeutic Approaches for Targeting Cancer Stem Cells
Pal, M., & Maiti, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_4 · Cited by 1
Strategies to Reduce Intratumoral Regulatory T Cells
Maherzi, C., Onodi, F., Tartour, É., Terme, M., & Tanchot, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_29 · Cited by 1
Self-citationMechanisms of immune suppression in glioblastoma
Ellsworth, S. G., & Grossman, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819755-4.00016-3 · Cited by 1
Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_16 · Cited by 1
Yu, B., Yoo, D., Kim, K. H., Kim, T. W., Park, S., Kim, Y., Son, Y., Kim, J., Noh, I., Whang, C., et al. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202100151 · Cited by 1
The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment
Cisneros-Garza, L. E., González-Huezo, M. S., Moctezuma‐Velázquez, C., de Guevara-Cetina, L. L., Vilatobá, M., García‐Juárez, I., Alvarado-Reyes, R., Álvarez-Treviño, G. A., Allende‐Pérez, S., Bornstein-Quevedo, L., et al. (2022) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2022.01.004 · Cited by 1
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Elkrief, A., & Yu, H. A. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00449-1 · Cited by 1
Tao, Y. (2023) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2264 · Cited by 1
“As an multi-target TKI, lenvatinib could mainly target VEGF receptors for not only inhibiting the proliferation of tumor blood vessel but also performing immunomodulatory activity through the vascular endothelial growth factor A (VEGF-A) produced by the tumor cells which can upregulate the expression of immune inhibit…”
BackgroundChen, X., Li, Y., Qu, X., Ye, Y., Du, X., Zhou, R., Qu, Y., Zhu, Y.-J., & Zhang, H. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3550 · Cited by 1
Dual impact of radiation therapy on tumor-targeting immune responses
Mirjolet, C., Baude, J., & Galluzzi, L. (2023) · International review of cytology · doi:10.1016/s1937-6448(23)00114-4 · Cited by 1
Go, E., Yang, H., Lee, S. J., Yang, H. G., Shin, J. A., Lee, W. S., Lim, H. S., Chon, H. J., & Kim, C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2259212 · Cited by 1
“VEGF-trap (aflibercept) is a chimeric decoy protein composed of VEGFR1 domain 2 and VEGFR2 domain 3, which bind to and neutralize VEGF-A, VEGF-B, and PlGF. 33,34 VEGF-trap has been approved by the Food and Drug Administration for use in patients with colorectal cancer or age-related macular degeneration.”
BackgroundInfluentialZhao, J., Wang, Y.-S., Gu, H.-Y., Meng, Z.-N., Wang, F., Wu, G., & Zheng, A.-H. (2023) · Medicine · doi:10.1097/md.0000000000035243 · Cited by 1
Wang, T., Tang, F., Li, F., Yin, W., & Liang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1321195 · Cited by 1
“VEGF triggers the development of myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages, thus contributing to the creation of an immunosuppressive tumor microenvironment (30).”
BackgroundQin, H., Yan, H., Zhang, X. Y., Huang, Z., Chen, Y., Zhang, Y., Xiang, S., Zhang, Y., Yang, N., & Zeng, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390299 · Cited by 1
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Juneja, V. R., LaFleur, M. W., Manguso, R. T., & Sharpe, A. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_1 · Cited by 2
Renal cell carcinoma drug and cell therapy: today and tomorrow
Pushkin, A. A., Burda, Y. E., Sevast'yanov, A. A., Kulikovskiy, V. F., Burda, S. Y., Александровна, Г. П., Zvyagina, A. K., & Kulyushina, N. V. (2018) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.4.25251 · Cited by 1
“Combination of immunotherapy with targeted drugs, such as VEGFR inhibitors, is currently being tested (Voron et al. 2015).”
Nizam, A., Rhea, L. P., Gupta, B., & Aragon‐Ching, J. B. (2019) · Kidney Cancer · doi:10.3233/kca-190050 · Cited by 1
“Specifically, VEGF has been found to play a pivotal role in permissive immune suppression of the tumor microenvironment in part by enhancing PD-1 and other T-cell inhibitory checkpoints which theoretically could be reversed by the use of VEGF inhibitors [32].”
BackgroundChernykh, E. R., Leplina, O. Y., Tikhonova, M. A., Васильевич, Б. Е., & Ostanin, A. A. (2019) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2019-4-653-660 · Cited by 1
Vasilev, G., Krasimirova, E., Ivanova, M. G., Ivanova‐Todorova, E., Tumangelova-Yuzeir, K. D., Gancheva, R., Stoilov, R. M., & Kyurkchiev, D. S. (2019) · doi:10.35465/27.3.2019.pp44-54 · Cited by 1
“Описани са няколко механизъма: sVEGF-A може да потиска транскрипцията на NFkβ, което води до потискане на матурацията и намаляване на способността за антигенно представяне [23]; освен това sVEGF-A води до продукция на IDO, разтворим фактор с доказано имуносупресивно действие [19].”
BackgroundAjina, R., Aldeghaither, D. S., Jablonski, S. A., & Weiner, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12426-6 · Cited by 3
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.